Glepaglutide
Glepaglutide (ZP1848)
Clinical trials are ongoing or recently completed. Final approval has not been granted.
An investigational once-weekly injection being developed to help people with short bowel syndrome absorb more nutrients from food, reducing their dependence on nutrition delivered through an IV. A large clinical trial showed it significantly reduced the amount of IV nutrition patients needed.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
Side effect frequencies from the Phase 2 trial (N=18): stoma complications 72%, injection site reactions 61%, peripheral edema 56%, nausea and abdominal pain 44% each, polyuria and fatigue 33% each, abdominal distention, vomiting, and dizziness 28% each, cough and decreased appetite 22% each (PMID 30880176). Related or possibly related serious adverse events included abdominal pain, stoma obstruction, catheter-related sepsis, and infection of unknown origin (PMID 30880176). In the Phase 3 trial, anti-drug antibodies developed in 87% (61/70) of glepaglutide-treated patients but did not appear to affect efficacy or safety; serious adverse events were often catheter- or device-related infections occurring in both active and placebo arms (PMID 39708985). The Phase 3b open-label study described safety across 52 weeks as manageable (PMID 40774623). No deaths occurred during the Phase 2 trial (PMID 30880176).
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-14]